肝内胆管癌的转化治疗

肝内胆管癌是仅次于肝细胞肝癌最常见的肝脏恶性肿瘤之一，在我国肝内胆管癌的发病率处于较高水平。目前，肝内胆管癌的治疗仍以手术切除为主，但由于肝内胆管癌在早期多无特异性症状，患者常在确诊时即为晚期，失去手术机会。转化治疗是近些年被提出的新概念，其认为初始无法手术切除的恶性肿瘤可以通过多种治疗方式进行降期，从而使患者得到手术的机会，延长患者的生存时间。随着各种新型抗肿瘤药物的研发以及疗效的验证，肝内胆管癌的转化治疗也迎来了曙光。本文即围绕肝内胆管癌转化治疗的现状以及本团队在该领域的实践经验这两个方面进行阐述。

Conversion therapy of intrahepatic cholangiocarcinoma

Intrahepatic cholangiocarcinoma (ICC) is one of the most common malignant liver tumors after hepatocellular carcinoma, the incidence rate of which in our country is rather high. At present, surgical resection is still main treatment for ICC. However, due to the lack of specific symptoms at early stage, ICC patients are often diagnosed at late stage and loss of the opportunity of surgical treatments. Conversion therapy is a novel concept proposed recently. It demonstrated that malignant tumors that cannot be resected initially can be downsized by various treatments, so that patients obtained the chance of surgical treatments and get prolonged survival time. With the development of novel anti-tumor drugs, conversion therapy of ICC also is in the first flush of dawn. This review summarizes the current situation of ICC conversion therapy and our practical experience.